

PRESS RELEASE

October 22, 2012

SpinalCyte, LLC Reports the Addition of Nicholas Theodore, M.D. to Clinical Advisory Board

HOUSTON, Texas – **SpinalCyte, LLC**, a spinal technology company focused on autologous regrowth of the spinal disc nucleus using human dermal fibroblasts (HDFs), today announced the addition of Nicholas Theodore, M.D. to its Clinical Advisory Board. Dr. Theodore, Director of Neurosurgery Spine Program, Barrow Neurological Institute, is one of the top spine surgeons and researchers in the country.

“The SpinalCyte technology has the potential to change the approach we take to degenerative disc disease. I see a future where cell-based therapies are a large part of our treatment options and the unique technology being developed by SpinalCyte can be a game-changer”, remarked Dr. Theodore.

“We are thrilled to have such an esteemed clinician and researcher, join our team. Dr. Theodore is one of the top spine surgeons in the country and his further involvement with our technology is such a huge validation,” said Pete O’Heeron, Chief Executive Officer.

The nucleus pulposus is a gelatinous material that acts as a cushion or shock absorber to the spinal column. It functions to distribute hydraulic pressure in all directions within each disc under compressive loads. The nucleus pulposus consists of chondrocytes, collagenfibrils, and proteoglycan aggrecans.

About Nicholas Theodore, M.D.

Dr. Theodore graduated from Cornell University, where he was the recipient of a Cornell Tradition Academic Fellowship. He attended medical school at Georgetown University, where he graduated with honors. After completing his internship at Bethesda Naval Hospital, Dr. Theodore served as a Senior General Medical Officer with the United States Marine Corps in Okinawa, Japan. Dr. Theodore completed his neurosurgical residency and a fellowship in spinal surgery at Barrow Neurological Institute. After completing his residency in 2001, Dr. Theodore served as Chief of the Division of Neurosurgery at Naval Medical Center San Diego, overseeing the largest neurosurgery complement in the Navy.

In 2003 he joined the faculty at Barrow Neurological Institute, and assumed the position of Director of Neurotrauma. In 2004 he was appointed Associate Director of the Neurosurgery Residency Program at Barrow. Barrow’s Residency Program is the largest in the United States. In 2010 he was appointed Director of the Barrow Neurosurgery Spine Program.

Dr. Theodore is a Diplomate of the American Board of Neurological Surgery and a fellow of the American College of Surgeons. He is the author of numerous scientific publications and the recipient of many research awards, including a prestigious RO-1 grant awarded by the National Institutes of Health.

About SpinalCyte, LLC

Based in Houston, Texas, SpinalCyte, LLC is a spinal technology company founded in 2007 for the purpose of developing an innovative and autologous solution for nucleus replacement using human dermal fibroblasts. The goal of SpinalCyte is to develop a nucleus regrowth technology using autologous dermal cells harvested from the patient. To date, SpinalCyte has been funded entirely by angel investors.

Contact:

Pete O’Heeron, CEO

281.461.6211

pete@spinalcyte.com